[go: up one dir, main page]

NO20032905L - Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister - Google Patents

Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister

Info

Publication number
NO20032905L
NO20032905L NO20032905A NO20032905A NO20032905L NO 20032905 L NO20032905 L NO 20032905L NO 20032905 A NO20032905 A NO 20032905A NO 20032905 A NO20032905 A NO 20032905A NO 20032905 L NO20032905 L NO 20032905L
Authority
NO
Norway
Prior art keywords
receptor antagonists
heterocyclic derivatives
orexin receptor
derivatives useful
related heterocyclic
Prior art date
Application number
NO20032905A
Other languages
English (en)
Other versions
NO20032905D0 (no
NO326158B1 (no
Inventor
Hamed Aissaoui
Martine Clozel
Thomas Weller
Ralf Koberstein
Thierry Sifferlen
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20032905L publication Critical patent/NO20032905L/no
Publication of NO20032905D0 publication Critical patent/NO20032905D0/no
Publication of NO326158B1 publication Critical patent/NO326158B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20032905A 2000-12-27 2003-06-24 Nye benzazepiner og beslektede heterocykliske derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av slike samt slike forbindelser for anvendelse som medikament NO326158B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2000/013289 WO2002051232A2 (en) 2000-12-27 2000-12-27 Novel benzazepines and related heterocyclic derivatives
PCT/EP2001/015074 WO2002051838A1 (en) 2000-12-27 2001-12-19 Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
NO20032905L true NO20032905L (no) 2003-06-24
NO20032905D0 NO20032905D0 (no) 2003-06-24
NO326158B1 NO326158B1 (no) 2008-10-13

Family

ID=8164232

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032905A NO326158B1 (no) 2000-12-27 2003-06-24 Nye benzazepiner og beslektede heterocykliske derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av slike samt slike forbindelser for anvendelse som medikament

Country Status (18)

Country Link
US (1) US7192950B2 (no)
EP (1) EP1347967B1 (no)
JP (1) JP4219166B2 (no)
KR (1) KR100849569B1 (no)
CN (1) CN1261430C (no)
AT (1) ATE381560T1 (no)
AU (1) AU2002240855B2 (no)
BR (1) BR0116505A (no)
CA (1) CA2431982C (no)
DE (1) DE60132017T2 (no)
ES (1) ES2296825T3 (no)
HU (1) HUP0301665A3 (no)
IL (2) IL155806A0 (no)
MX (1) MXPA03004779A (no)
NO (1) NO326158B1 (no)
NZ (1) NZ525613A (no)
WO (2) WO2002051232A2 (no)
ZA (1) ZA200303697B (no)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7250410B2 (en) 2001-06-07 2007-07-31 Via Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CA2498091C (en) 2002-10-11 2011-03-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
ES2297413T3 (es) 2003-04-28 2008-05-01 Actelion Pharmaceuticals Ltd. Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina.
WO2005005392A1 (en) * 2003-07-07 2005-01-20 Ionix Pharmaceuticals Limited Azacyclic compounds as inhibitors of sensory neurone specific channels
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
KR100848747B1 (ko) * 2004-03-01 2008-07-25 액테리온 파마슈티칼 리미티드 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
GB0500300D0 (en) * 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
WO2007105177A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
PL2010493T3 (pl) * 2006-04-12 2016-08-31 Merck Sharp & Dohme Pirydyloamidy jako antagoniści kanałów wapniowych typu t
JP2009535324A (ja) 2006-04-26 2009-10-01 アクテリオン ファーマシューティカルズ リミテッド 新規なピラゾロ−テトラヒドロピリジン誘導体
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
ATE528306T1 (de) * 2006-11-02 2011-10-15 Piramal Life Sciences Ltd Benzoxazepin-verbindungen, ihre herstellung und verwendung
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101568542B (zh) 2006-12-22 2013-03-27 埃科特莱茵药品有限公司 5,6,7,8-四氢-咪唑并[1,5-a]吡嗪衍生物
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
ATE512963T1 (de) * 2007-04-04 2011-07-15 Hoffmann La Roche Heterocyclen als orexinantagonisten
EP2146722A4 (en) 2007-05-10 2011-08-03 Amr Technology Inc ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
JP4881476B2 (ja) 2007-05-23 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション ピリジルピペリジン・オレキシン受容体アンタゴニスト
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2187931A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a combination of cart peptides as a therapeutic agent
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト
DK2227455T3 (da) * 2007-12-28 2012-01-23 Actelion Pharmaceuticals Ltd Trisubstitueret 3,4-dihydro-1H-isoquinolinforbindelse, fremgangsmåde til fremstillingen og dens anvendelse
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CA2763008A1 (en) * 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2504316A1 (en) 2009-11-23 2012-10-03 MSD Oss B.V. Heterocylic compounds as antagonists of the orexin receptors
FR2956401B1 (fr) 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201690035A1 (ru) 2011-02-25 2016-05-31 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
PT2758060T (pt) 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2014006402A1 (en) * 2012-07-03 2014-01-09 Heptares Therapeutics Limited Orexin receptor antagonists
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病性三環式化合物
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2781217A1 (en) 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
JP6883045B2 (ja) 2016-02-12 2021-06-02 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag オレキシン受容体調節因子としてのハロ置換ピペリジン
EP3454857A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
GB201718256D0 (en) * 2017-11-03 2017-12-20 Heptares Therapeutics Ltd Ox1 antagonists
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CN119977904A (zh) * 2025-02-18 2025-05-13 合肥工业大学 一种苯并氧(碳/硫)氮杂䓬类化合物及其在医学上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236838A (en) * 1964-06-09 1966-02-22 Hoffmann La Roche Certain 1-substituted-benzodiazepin-2-one compounds
US3480714A (en) * 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
JP2002527433A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンd3受容体のモジュレーター(抗精神病薬)として有用なテトラヒドロベンズアゼピン誘導体

Also Published As

Publication number Publication date
AU2002240855B2 (en) 2006-08-17
JP4219166B2 (ja) 2009-02-04
EP1347967B1 (en) 2007-12-19
BR0116505A (pt) 2004-02-03
JP2004516324A (ja) 2004-06-03
NZ525613A (en) 2005-01-28
HUP0301665A3 (en) 2008-12-29
NO20032905D0 (no) 2003-06-24
MXPA03004779A (es) 2003-09-25
ES2296825T3 (es) 2008-05-01
CN1481380A (zh) 2004-03-10
DE60132017T2 (de) 2008-12-04
ATE381560T1 (de) 2008-01-15
WO2002051838A1 (en) 2002-07-04
IL155806A0 (en) 2003-12-23
ZA200303697B (en) 2004-08-13
CA2431982A1 (en) 2002-07-04
NO326158B1 (no) 2008-10-13
HUP0301665A2 (en) 2008-07-28
KR20030069199A (ko) 2003-08-25
CN1261430C (zh) 2006-06-28
CA2431982C (en) 2010-07-20
US7192950B2 (en) 2007-03-20
KR100849569B1 (ko) 2008-07-31
WO2002051232A2 (en) 2002-07-04
IL155806A (en) 2008-03-20
DE60132017D1 (de) 2008-01-31
US20040058912A1 (en) 2004-03-25
EP1347967A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
MXPA03004780A (es) Nuevas sulfamidas.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
MY140724A (en) Novel arylethene-sulfonamides
NO20022971L (no) Butyndiol-derivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees